Regenxbio Inc
RGNX
NASDAQ
Biotechnology
$10.77
USD
+0.11 (+0.98%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $701.72M
Volume 792.3K
Revenue
$174.48M
TTM
+12.0%
YoY
Gross Margin
86%
TTM
+4.8%
YoY
Net Income
$-196.43M
TTM
-11.9%
YoY
Operating Cash Flow
$-246.67M
TTM
-180.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 21.4 | 29.7 | 30.3 | 6.4 | 108.0 |
YoY Growth | -4.2% | +22.9% | +43.0% | -92.8% | +405.7% |
Cost of Revenue | 5.2 | 5.7 | 5.9 | 11.1 | 1.0 |
Gross Profit | 16.2 | 24.0 | 24.4 | -4.7 | 107.0 |
Selling, General & Administrative | 19.9 | 20.3 | 22.4 | 21.3 | 21.6 |
Other Operating Expenses | 0.0 | 0.1 | 0.1 | 0.0 | 0.0 |
Total Operating Expenses | 79.4 | 76.4 | 82.0 | 78.7 | 77.7 |
Operating Income | -63.3 | -52.4 | -57.6 | -83.4 | 29.3 |
EBITDA | -59.4 | -48.5 | -53.8 | -79.5 | 33.0 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | -7.6 | -9.5 | -9.5 | -6.7 | -6.6 |
Income Before Income Taxes | -70.9 | -61.9 | -67.1 | -90.1 | 22.7 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -70.9 | -61.9 | -67.1 | -90.1 | 22.7 |
Consolidated Net Income / Loss | -70.9 | -61.9 | -67.1 | -90.1 | 22.7 |
Net Income Attributable to Common Shareholders | -70.9 | -61.9 | -67.1 | -90.1 | 22.7 |
Basic EPS | -$1.38 | -$1.20 | -$1.30 | -$1.72 | $0.43 |
Diluted EPS | -$1.38 | -$1.20 | -$1.30 | -$1.72 | $0.43 |
Basic Shares Outstanding | 51.5M | 51.7M | 51.8M | 52.4M | 52.8M |
Diluted Shares Outstanding | 51.5M | 51.7M | 51.7M | 52.4M | 53.0M |